Meritech Capital Associates V’s 10x Genomics TXG Stock Holding History

Meritech Capital Associates V’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-494,236	Closed	-$9.61M	–	3
2024 Q2	$9.61M	Hold	494,236	–	–	3.3%	3
2024 Q1	$18.5M	Hold	494,236	–	–	6.2%	3
2023 Q4	$27.7M	Hold	494,236	–	–	6.73%	3
2023 Q3	$20.4M	Sell	494,236 -256,266	-34%	-$13.3M	6.49%	3
2023 Q2	$41.9M	Hold	750,502	–	–	10.04%	3
2023 Q1	$41.9M	Sell	750,502 -311,180	-29%	-$14.5M	8.8%	4
2022 Q4	$38.7M	Hold	1,061,682	–	–	9.44%	3
2022 Q3	$30.2M	Hold	1,061,682	–	–	5.16%	4
2022 Q2	$48M	Sell	1,061,682 -274,571	-21%	-$14.2M	7.43%	4
2022 Q1	$102M	Sell	1,336,253 -274,571	-17%	-$24M	9.59%	4
2021 Q4	$240M	Sell	1,610,824 -183,047	-10%	-$28M	7.68%	3
2021 Q3	$261M	Hold	1,793,871	–	–	7.8%	3
2021 Q2	$351M	Sell	1,793,871 -329,485	-16%	-$59.6M	7.51%	3
2021 Q1	$384M	Sell	2,123,356 -457,619	-18%	-$79M	9.49%	3
2020 Q4	$365M	Buy	+2,580,975	New	+$375M	30.7%	2

Other funds holding TXG

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return

Meritech Capital Associates V's TXG Position: Q3 2024 in Review

Meritech Capital Associates V sold out of 10x Genomics (TXG) in Q3 2024, closing a stake of 494,236 shares — an estimated $9.61M sold.

Meritech Capital Associates V first reported a position in TXG in Q4 2020 and held it in 15 quarters. The position peaked at $384M in Q1 2021. 266 funds tracked by Wall St. Rank hold TXG as of Q3 2024.

Meritech Capital Associates V reported no remaining 10x Genomics position as of Q3 2024 after selling out during the quarter.
Meritech Capital Associates V sold 494,236 10x Genomics shares in Q3 2024, an estimated $9.61M.
Meritech Capital Associates V first reported a position in 10x Genomics in Q4 2020 and held it in 15 quarters.
Meritech Capital Associates V's 10x Genomics position peaked at $384M in Q1 2021.
266 funds tracked by Wall St. Rank held 10x Genomics as of Q3 2024.

Based on Meritech Capital Associates V's 13F filing for Q3 2024, filed 14 Nov 2024.